

Table 1.1 FDA-Approved Anticancer Drugs Described in Chapter 2—cont'd

Drug	Mechanism of Action	Approval Date (First Indication)
Eniluracil	DNA synthesis inhibitor	2005
Nelarabine (Arranon [®])	DNA synthesis inhibitor	2005
Pegaspargase (Oncaspar [®])	Hydrolysis of circulating L-asparagine	2006
Fludarabine (Fludara [®])	DNA synthesis inhibitor	2008
Pralatrexate (Foloty [®])	Dihydrofolate reductase inhibitor	2009
<i>Erwinia chrysanthemi</i> asparaginase (Erwinaze [®])	Hydrolysis of circulating L-asparagine	2011

Table 1.2 FDA-Approved Anticancer Drugs Described in Chapter 3

Drug	Mechanism of Action	Approval Date (First Indication)
Medroxyprogesterone (Provera [®])	Gestagen receptor agonist	1959
Testolactone (Teslac [®])	Steroidal aromatase inhibitor	1970
Mitotane (Lysodren [®])	Glucocorticoid biosynthesis inhibitor	1970
Megestrol acetate (Megace [®])	Gestagen receptor agonist	1971
Tamoxifen (Nolvadex [®])	Antiestrogen	1977
Aminoglutethimide (Cytadren [®])	Aromatase inhibitor	1981
Leuprorelin (Lupron [®])	GnRH (LHRH) agonist	1985
Lupron Depot [®]		1996
Flutamide (Eulexin [®] , Drogenil [®])	Antiandrogen	1989
Goserelin (Zoladex [®])	GnRH (LHRH) agonist	1989
Finasteride (Proscar [®])	5 α -Reductase inhibitor	1992
Bicalutamide (Casodex [®])	Antiandrogen	1995
Anastrozole (Arimidex [®])	Aromatase inhibitor	1995
Goserelin acetate (Zoladex [®])	GnRH (LHRH) agonist	1996
Nilutamide (Nilandron [®])	Antiandrogen	1996
Letrozole (Femara [®])	Aromatase inhibitor	1997
Octeotride (Sandostatin [®])	Somatostatin analog	1998
Exemestane (Aromasin [®])	Aromatase inhibitor	1999
Alitretinoin (Panretin [®])	Retinoid	1999
Bexarotene (Targetin [®])	Retinoid	1999
Triptorelin (Trelstar [®])	GnRH (LHRH) agonist	2000
Fulvestrant (Faslodex [®])	Antiestrogen	2002
Dutasteride (Avodart [®])	5 α -Reductase inhibitor	2002
Abarelix (Plenaxis [®])	GnRH (LHRH) antagonist	2003
Histrelin (Vantas [®])	GnRH (LHRH) agonist	2004
Raloxifene (Evista [®])	Antiestrogen	2007
Degarelix (Firmagon [®])	GnRH (LHRH) antagonist	2008
Abiraterone (Zytiga [®])	CYP17A1 inhibitor	2011
Enzalutamide (Xtandi [®])	Antiandrogen	2012
Pasireotide (Signifor [®])	Somatostatin analog	2012